Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

6.91USD
20 Feb 2018
Change (% chg)

$0.31 (+4.70%)
Prev Close
$6.60
Open
$6.56
Day's High
$7.33
Day's Low
$6.56
Volume
541,754
Avg. Vol
160,806
52-wk High
$15.51
52-wk Low
$5.02

Chart for

About

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of... (more)

Overall

Beta: --
Market Cap(Mil.): $377.79
Shares Outstanding(Mil.): 33.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

30 Jan 2018

Bellicum's cancer drug trials on clinical hold, shares tumble

Jan 30 Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

30 Jan 2018

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

30 Jan 2018

BRIEF-Bellicum Enters Into Agreement With Oxford Finance To Borrow $35 Mln - SEC Filing

* BELLICUM PHARMACEUTICALS SAYS ENTERED INTO AGREEMENT WITH OXFORD FINANCE LLC TO BORROW $35.0 MILLION IN A SINGLE TERM LOAN - SEC FILING Source text: (http://bit.ly/2BhY3X0) Further company coverage:

21 Dec 2017

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​

07 Nov 2017

Earnings vs. Estimates